Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.263
+0.004 (1.55%)
At close: Nov 4, 2024, 4:00 PM
0.256
-0.007 (-2.62%)
Pre-market: Nov 5, 2024, 5:32 AM EST
Lyra Therapeutics Revenue
Lyra Therapeutics had revenue of $598.00K in the quarter ending June 30, 2024, with 30.57% growth. This brings the company's revenue in the last twelve months to $1.82M, up 47.01% year-over-year. In the year 2023, Lyra Therapeutics had annual revenue of $1.56M with 14.31% growth.
Revenue (ttm)
$1.82M
Revenue Growth
+47.01%
P/S Ratio
8.96
Revenue / Employee
$20,682
Employees
88
Market Cap
17.21M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cara Therapeutics | 11.00M |
Synlogic | 3.17M |
Innovative Eyewear | 1.53M |
GeoVax Labs | 300.68K |
AIM ImmunoTech | 201.00K |
Kazia Therapeutics | 382.00 |
LYRA News
- 21 days ago - Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - GlobeNewsWire
- 5 weeks ago - Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - GlobeNewsWire
- 2 months ago - Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - 3 'Buy-Rated' Biotech Stocks Under $10 - Seeking Alpha
- 6 months ago - Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire